Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers. Issue 2 (25th January 2023)

• Record Type: Journal Article
• Authors: Verhaak, Allison; Bakaysa, Stephanie; Johnson, Amy; Veronesi, Maria; Williamson, Anne; Grosberg, Brian
• Is Part Of: Headache. Volume 63:Issue 2(2023)
• Page Start: 211
• Page End: 221
• Publication Date: 2023-01-25
• Subjects: migraine -- pregnancy -- treatment -- women's healthcare; Headache -- Periodicals; Headache -- Periodicals; 616.8491
• DOI: 10.1111/head.14436
• Languages: English
• ISSNs: 0017-8748

Abstract

Abstract: Objective: The objective of this study was to assess women's healthcare providers' treatment practices for pregnant women with migraine. Background: Migraine is associated with several maternal and fetal complications during pregnancy, including preeclampsia and preterm birth. Migraine treatment during pregnancy can present significant challenges due to lack of controlled clinical trials and risks associated with specific medications. Methods: Women's healthcare providers were queried regarding practice patterns and comfort with use of acute and preventive migraine treatments during pregnancy. The survey was distributed online. Results: The survey was completed by 92 women's healthcare providers (response rate 22.9% [92/402]), with most specializing in general obstetrics and gynecology (91% [83/92]). Approximately one‐fourth (26% [24/92]) of respondents indicated they counseled women on migraine treatment in pregnancy as early as before pregnancy contemplation, while over one‐third (35% [32/92]) counseled on migraine treatment once the patient became pregnant. The majority of respondents reported feeling somewhat or very comfortable with recommending (63% [58/92]) or continuing (64% [59/92]) acute treatments for pregnant patients with migraine, with highest comfort levels for acetaminophen (100% [92/92] for prescribing or continuing) and caffeine (94% [85/90] prescribing, 91% [82/90] continuing). Higher levels of discomfort were reported with triptans (88% [80/91] rarely or never prescribe during pregnancy). Survey respondents felt less comfortable with recommending preventive migraine treatments to pregnant patients (40% [37/92] somewhat or very comfortable), compared with a higher comfort level with continuing preventive medications (63% [58/92] somewhat or very comfortable). Highest comfort levels were reported with use of magnesium (69% [63/91] comfortable prescribing, 82% [75/92] comfortable continuing) and non‐pharmacologic approaches (70% [62/89] comfortable prescribing, 84% [75/89] comfortable continuing). Nearly 40% (35/92) of respondents reported that they typically refer to neurologists or headache specialists for migraine treatment during pregnancy. Conclusion: This survey of women's healthcare providers revealed varying levels of comfort regarding migraine management during pregnancy, and highlights the need for additional education regarding migraine treatment safety data during pregnancy.